Cite
HARVARD Citation
Li, T. et al. (2016). First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors. Journal of hematology & oncology. 9 (1), pp. 1-9. [Online].